Severe epistaxis with tyrosine kinase inhibitors.
Hall
P S
PS
Kancherla
K
K
Sastry
P S R K
PS
Brown
J E
JE
D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary; D004844:Epistaxis / Q000139:chemically induced*; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib
D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib